Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, which was $0.06 below consensus estimates [3]. - The company's revenue for Q1 2025 was $598.12 million, missing consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders, as stated by the President and CEO of Globus [3].

Core Viewpoint - A class action securities lawsuit has been filed against DoubleVerify Holdings, Inc. alleging securities fraud that negatively impacted investors between November 10, 2023, and February 27, 2025 [1][2]. Group 1: Allegations of the Lawsuit - The lawsuit claims that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, limiting the company's technological capabilities and increasing competition from platforms like Meta and Amazon [2]. - It is alleged that the monetization of DoubleVerify's Activation Services was hindered due to the high costs and time required for technology development for closed platforms [2]. - The complaint states that it would take several years for DoubleVerify's Activation Services related to certain closed platforms to become profitable [2]. - Competitors were reportedly better positioned to integrate AI into their offerings on closed platforms, which negatively affected DoubleVerify's competitive stance and profitability [2]. - The company is accused of systematically overbilling customers for ad impressions served to bots operating from known data centers [2]. - The risk disclosures provided by DoubleVerify were claimed to be materially false and misleading, presenting adverse facts as mere possibilities [2]. - As a result of these issues, the positive statements made by the defendants regarding the company's business and prospects were deemed materially false or misleading [2]. Group 2: Next Steps for Affected Investors - Investors who suffered losses in DoubleVerify Holdings, Inc. during the specified timeframe have until July 21, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Companies, Inc. ("Rocket Companies" or the "Company") (NYSE: RKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket Companies investors who were adversely affected by alleged securities fraud between March 29, 2021 and April 1, 2021. Follow the link below to get more information and be contacted by a member of our team: https://www.zlk.com/pslra-1/rocke ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Redwire Corporation and its officers or directors [1] Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, which missed consensus estimates by $13.14 million and marked a 30.1% year-over-year decline [3] - The company attributed the revenue decline to delays in U.S. government contract awards due to leadership transitions at agencies like NASA and the Space Development Agency, as well as shifting budget priorities under the Trump administration [3] Stock Market Reaction - Following the financial results announcement, Redwire's stock price decreased by $0.75 per share, or 6.63%, closing at $10.56 per share on May 12, 2025 [4]

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global Management, Inc. (NASDAQ: ABL) focused on whether Abacus Global and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Abacus Global investigation or if you are an Abacus Global investor who suff ...

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions [3]. - The company was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded entity [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Fortrea exaggerated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing financial results for Q4 and full year 2024, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group PLC on behalf of purchasers of American Depositary Shares (ADSs) during the period from January 13, 2021, to July 28, 2024, due to alleged misleading statements regarding the safety of its cow's milk-based formula, Enfamil, for preterm infants [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt failed to inform investors that preterm infants consuming Enfamil were at an increased risk of developing necrotizing enterocolitis (NEC) [5]. - It is alleged that Reckitt's positive statements about its business and operations were materially false and misleading, lacking a reasonable basis during the class period [5]. - Investors reportedly suffered damages when the true details about the risks associated with Enfamil became public [5]. Group 2: Legal Representation - The Rosen Law Firm is representing the investors and encourages potential class members to select qualified counsel with a successful track record in securities class actions [4]. - Investors who purchased Reckitt ADSs may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the court by August 4, 2025, to represent other class members in the litigation [1][3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Schrödinger, Inc. and its officers or directors [1] Group 1: Company Developments - On May 20, 2025, Schrödinger announced the departure of its chief financial officer, Geoffrey Porges, which led to a significant stock price decline of $2.03 per share, or 8.62%, closing at $21.53 per share [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Sanofi and its officers or directors [1] Group 1: Company Performance - On May 30, 2025, Sanofi released mixed results from a Phase 3 program for itepekimab, an antibody therapy for chronic obstructive pulmonary disease, with the AERIFY-1 trial meeting its primary endpoint, while the AERIFY-2 trial did not [2] - Following the announcement, Sanofi's American Depositary Receipt (ADR) price dropped by $2.98, or 5.69%, closing at $49.37 per ADR on the same day [3] Group 2: Legal Investigation - The investigation by Pomerantz LLP is aimed at determining if there were any fraudulent activities or misconduct related to Sanofi's business practices [1] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Zeo Energy Corp and its officers or directors [1] Group 1: Company Compliance Issues - On May 29, 2025, Zeo announced it received a notice from Nasdaq regarding non-compliance with periodic filing requirements due to the failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 by the due date of May 15, 2025 [3] - Following this announcement, Zeo's stock price decreased by $0.34 per share, representing a 9.91% decline, closing at $3.09 per share on May 30, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4]